Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
UTHR United Therapeutics
259.680-4.550-1.72%
Close
01/27 16:00 ET
259.6800.0000.00%
Post Mkt Price 01/27 16:17 ET
High
263.970
Open
263.500
Turnover
56.68M
Low
258.170
Pre Close
264.230
Volume
218.00K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,076,800.00 in Stock
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the business's stock in a transaction dated Thursday, January 19th. The stock was sold at an average p
United Therapeutics Co. (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" From Brokerages
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) has received a consensus rating of "Moderate Buy" from the fourteen brokerages that are covering the firm, Marketbeat reports. Two research analyst
Financial Gravity Asset Management Inc. Has $2.34 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)
Financial Gravity Asset Management Inc. lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 146.0% in the third quarter, HoldingsChannel reports. The institutional
Martine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an
Cwm LLC Has $66,000 Stake in United Therapeutics Co. (NASDAQ:UTHR)
Cwm LLC grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 132.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and
United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,092,160.00 in Stock
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction on Friday, January 13th. The shares were sold at an average price of
Seizert Capital Partners LLC Has $7.16 Million Position in United Therapeutics Co. (NASDAQ:UTHR)
Seizert Capital Partners LLC lowered its position in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 1.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Ex
Tekla Capital Management LLC Increases Position in United Therapeutics Co. (NASDAQ:UTHR)
Tekla Capital Management LLC lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 62.6% during the third quarter, Holdings Channel reports. The fund owned 117,377 s
United Therapeutics Co. (NASDAQ:UTHR) Stock Position Lessened by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 36.9% in the 3rd quarter, according to the company in its most recent discl
Argus Raises United Therapeutics (NASDAQ:UTHR) Price Target to $300.00
United Therapeutics (NASDAQ:UTHR – Get Rating) had its target price hoisted by Argus from $250.00 to $300.00 in a research note published on Wednesday morning, Benzinga reports. They currently have a
Company Overview
More
United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.
CEO： Dr. Martine A. Rothblatt
Market： NASDAQ
Listing Date： 06/17/1999
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet